The Supreme Court has issued notice to Cadila Healthcare Ltd for allegedly supplying spurious drugs "unfit for consumption". A bench headed by Justice S.B. Sinha sought response from the pharma company on a petition filed by Rajasthan government challenging quashing of the criminal proceedings initiated against the company.
The Rajasthan HC had ignored the report of drug analyst, which confirmed that the contents of dexamethozine Hydroclorofide in Dexona Injuction was only 61.25 per cent which was "dangerous to life of human beings," the Rajasthan government counsel said. According to the State, the sample of Dexona 2 ml batch collected from a medical store in August 1998 was of standard quality. The drug inspector after had sent the sample for analysis to Central Indian Pharmacopoeia Laboratory, Ghaziabad. The plea taken by the company that it could not apply for re-testing of samples cannot sustain especially when they were also given the samples sent for analysis. The State had filed a complaint against Cadila as the sample of the injunction collected had failed to confirm to the claim in respect of assay.
No comments:
Post a Comment